Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 5Renal Insufficiency 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Dexamethasone 50Melphalan 29Cyclophosphamide 25Bortezomib 24Filgrastim 18Calcium Dobesilate 18Peripheral Blood Stem Cell Transplantation 16daratumumab 13pomalidomide 10dexamethasone acetate 8Lenalidomide 8fludarabine phosphate 7ixazomib 6dexamethasone 21-phosphate 6Whole-Body Irradiation 6Mycophenolic Acid 6venetoclax 5birtamimab 5auricularum 5Thalidomide 5Granulocyte Colony-Stimulating Factor 5Cyclosporine 5Busulfan 5Radiotherapy 4Interferon-alpha 4Etoposide 4Carboplatin 4Biopsy 4sargramostim 3miridesap 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunoglobulin Light-chain Amyloidosis × melflufen × Plasma cell × Clear all
NCT04115956 2022-03-28

A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis

Oncopeptides AB

Phase 1 Terminated
6 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡